ESC Premium Access

More than the half number of the severe CAD patients without features of metabolic syndrome had hyperlipoprotein(a)-emia

Topic: Metabolic Syndrome, Insulin, Insulin Resistance

Presentation

About the speaker

Doctor Takashi Kasahara

San-in Rosai Hospital, Yonago (Japan)
0 follower

224 more presentations in this session

High risk characteristics in patients with hypertrophic cardiomiyopathy for predicting cardiovascular events

Speaker: Doctor B. Keskin (Istanbul, TR)

Thumbnail

Cardiac biomarkers as prognosticators among SARS-CoV-19 patients in a tertiary hospital in Philippines

Speaker: Doctor R. Ong (Makati, PH)

Thumbnail

Prevalence of atherosclerosis risk factors in Egyptian patients with acute coronary syndromes; final data of the nationwide cross-sectional CardioRisk project

Speaker: Doctor A. Bendary (Benha, EG)

Thumbnail

SF-12 Physical and Mental Health Scales predict cardiovascular events after hospitalization

Speaker: Mr R. Gascuena (Leganes, ES)

Thumbnail

Comparison of traditional versus artificial intelligence based coronary artery disease risk prediction scores in young patients with acute coronary syndrome

Speaker: Doctor S. Vohra (Lucknow, IN)

Thumbnail

Access the full session

Risk Factors and Prevention ePosters

Speakers: Doctor T. Kasahara, Doctor B. Keskin, Doctor R. Ong, Doctor A. Bendary, Mr R. Gascuena...
Thumbnail

About the event

Image

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Related content

ESC Premium Access

Target populations and treatment cost for bempedoic acid and PCSK9 inhibitors: a simulation study in a contemporary CAD cohort

27 August 2021

ESC Premium Access

PCSK9 inhibition with alirocumab decreases plasma lipoprotein(a) concentration by a dual kinetic mechanism of action

27 August 2021

ESC Premium Access

Treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe: baseline demographics from the multinational observational SANTORINI study

27 August 2021

This platform is supported by

logo Novo Nordisk